Gąsowska-Bodnar, A.; Gąsowska-Bajger, B.; Żołnierek, A.; Żołnierek, J.; Bodnar, L.
PARP Inhibitors and the Risk of Serum Creatinine Elevation in Ovarian Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cancers 2026, 18, 1226.
https://doi.org/10.3390/cancers18081226
AMA Style
Gąsowska-Bodnar A, Gąsowska-Bajger B, Żołnierek A, Żołnierek J, Bodnar L.
PARP Inhibitors and the Risk of Serum Creatinine Elevation in Ovarian Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cancers. 2026; 18(8):1226.
https://doi.org/10.3390/cancers18081226
Chicago/Turabian Style
Gąsowska-Bodnar, Agnieszka, Beata Gąsowska-Bajger, Aleksandra Żołnierek, Jakub Żołnierek, and Lubomir Bodnar.
2026. "PARP Inhibitors and the Risk of Serum Creatinine Elevation in Ovarian Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials" Cancers 18, no. 8: 1226.
https://doi.org/10.3390/cancers18081226
APA Style
Gąsowska-Bodnar, A., Gąsowska-Bajger, B., Żołnierek, A., Żołnierek, J., & Bodnar, L.
(2026). PARP Inhibitors and the Risk of Serum Creatinine Elevation in Ovarian Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cancers, 18(8), 1226.
https://doi.org/10.3390/cancers18081226